Compound: voglibose
SMILES: O[C@]1([C@@H](O)[C@H](O)[C@@H](O)[C@H](C1)NC(CO)CO)CO
InChIKey: FZNCGRZWXLXZSZ-CIQUZCHMSA-N
Synonyms: voglibose, 83480-29-9, Basen, Glustat, Voglibosa, AO-128, Voglibosum, A-71100, N-(1,3-Dihydroxy-2-propyl)valiolamine, DTXSID2021442, S77P977AG8, DTXCID901442, (1S,2S,3R,4S,5S)-5-[(1,3-dihydroxypropan-2-yl)amino]-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol, (1S,2S,3R,4S,5S)-5-((1,3-dihydroxypropan-2-yl)amino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol, RefChem:902044, A10BF03, 3,4-Dideoxy-4-(2-hydroxy-1-(hydroxymethyl)ethylamino)-2-C-(hydroxymethyl)-D-epi-inositol, (1S,2S,3R,4S,5S)-5-((1,3-dihydroxypropan-2-yl)amino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol, (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol, CHEMBL476960, 3,4-Dideoxy-4-((2-hydroxy-1-(hydroxymethyl)ethyl)amino)-2-C-(hydroxymethyl)-D-epi-inositol, AO 128, MFCD00865496, Basen OD, C10H21NO7, Voglibose [INN], (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol, (1S,2S,3R,4S,5S)-5-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino}-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol, CAS-83480-29-9, Basen (TN), Voglibose [USAN:INN], Voglibosum [INN-Latin], Voglibosa [INN-Spanish], UNII-S77P977AG8, CCRIS 4540, NCGC00164595-01, (1S,2S,3R,4S,5S)-5-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol, 112653-29-9, VOG, Voglibose Impurity 34, VOGLIBOSE [JAN], VOGLIBOSE [MI], VOGLIBOSE [USAN], GlyTouCan:G23864GM, VOGLIBOSE [MART.], SCHEMBL5882, VOGLIBOSE [WHO-DD], A 71100, MLS003882582, Voglibose - Bio-X trade mark, orb1300524, Voglibose (JP18/USAN/INN), CHEBI:32300, DTXSID501031239, GLXC-06681, HMS3414A17, HMS3678A17, Voglibose, >=97.0% (TLC), G23864GM, HY-B0025, MSK10642, Tox21_112220, BDBM50263044, s4101, AKOS015950839, Tox21_112220_1, CCG-267119, DB04878, MV06910, NCGC00164595-02, 3,4-DIDEOXY-4-[[2-HYDROXY-1-(HYDROXYMETHYL)ETHYL]AMINO]-2-C-(HYDROXYMETHYL)-D-EPINOSITOL, BV164530, SMR002530327, SY108971, NS00069197, D01665, AB01566929_01, F818267, SR-01000883931, Q7939403, SR-01000883931-1, BRD-K66850609-001-01-7, BRD-K66850609-001-05-8, BRD-K66850609-001-07-4, 3,4-Dideoxy-[2-hydroxy-1-(hydroxyethyl)ethyl] amino-1-C-(hydroxymethyl)-1,2,3,4-cyclohexaneterol, 3,4-Dideoxy-4-[[2-hy droxy-1-(hydr oxymethyl)ethyl]amino]-2-C-(hydroxymethyl)-D-epiinositol, D-epi-Inositol, 3,4-dideoxy-4-((2-hydroxy-1-(hydroxymethyl)ethyl)amino)-2-C-(hydroxymethyl)-
Theoretical properties:
molecular_formula: C10H21NO7
molecular_weight: 267.28 g/mol
exact_mass: 267.13180201 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 8
hydrogen_bond_acceptor_count: 8
rotatable_bond_count: 5
heavy_atom_count: 18
topological_polar_surface_area: 154 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
solubility: 1.90e+02 g/L
Descriptions:
pubchem: Voglibose is an organic molecular entity.
chembl: VOGLIBOSE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Voglibose (INN and USAN, trade name Voglib, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lowering postprandial blood glucose levels in people with diabetes mellitus.  Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company. Voglibose was discovered in 1981, and was first launched in Japan in 1994, under the trade name BASEN, to improve postprandial hyperglycemia in diabetes mellitus.
Postprandial hyperglycemia (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal.
There are three major drugs which belong to this class, acarbose, miglitol and voglibose, of which voglibose is the newest.